Researchers explored why only 40 percent of patients responded to Amgen's Imdelltra using TellBio's liquid biopsy test and ...
We conducted a systematic meta-analysis of 30 studies involving 3,287 patients with postoperative NSCLC to evaluate the diagnostic performance of ctDNA-based MRD testing for recurrence detection and ...
A study led by scientists at NYU Langone Health and its Perlmutter Cancer Center has shown that monitoring blood levels of DNA fragments shed by dying tumor cells may accurately predict skin cancer ...
Researchers are exploring the use of circulating tumor (ct) DNA to guide treatment decisions and aid in clinical trial selection for patients with renal cell carcinoma (RCC). A recent study in JCO ...
Circulating tumor DNA (ctDNA), small pieces of DNA released from dying tumor cells into the bloodstream, can be easily and non-invasively identified and examined through a simple blood test. This ...
Glioblastoma (GBM) is an aggressive brain tumor characterized by marked intra- and inter-tumoral heterogeneity and inevitable recurrence. Although extracranial metastasis is rare, circulating tumor ...
Data confirms Versamune® HPV has potential as a broadly effective treatment of HPV16-associated cancers – Initiation of Phase 3 trial in HPV16-positive HNSCC planned for Q1 2025 Versamune® HPV + CRT ...
Cancer is one of the leading causes of death globally, with nearly 20 million new cases and 9.7 million deaths in 2022. Early detection plays a crucial role in reducing cancer-related morbidity and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results